U.K. cost gatekeepers OK Daiichi's Lixiana; J&J Vision Care targets young females with E! partnership;

> The U.K.'s cost watchdog has recommended Daiichi Sankyo's Lixiana for treating and preventing potentially fatal blood clots. Release

> In a Phase II study, Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 prospect, Praluent, produced LDL cholesterol reductions of more than 60% in Japanese patients. Release

> Johnson & Johnson ($JNJ) Vision Care has partnered up with fashion and entertainment broadcaster E! Entertainment Television to reach a young, fashion-forward, female audience with its 1-Day Acuvue Define range of products. More

> In a Phase II study, Roche's ($RHHBY) investigational immunotherapy atezolizumab shrank tumors in people with a specific type of bladder cancer. Release

> Roche ($RHHBY) has launched its FDA-cleared diabetes app with an insulin calculator in the U.S. More

And Finally... The Obama administration has issued new rules that allow closely held for-profit corporations with religious objections to opt out of providing women with insurance coverage for contraceptives. More (sub. req.)

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.